Showing results (151-160 of 242) with videos related to
Sort By:
Pageof 25
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2014
Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancerMartin R Stockler, Felix Hilpert, Michael Friedlander, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 19, 2025
Patterns of care and development of quality indicators in patients with non-epithelial and rare ovarian tumors in Australia: insights from the National Gynae-Oncology RegistryYeh Chen Lee, Aleesha Whitely, Michael Burling, et al.Future Oncology (London, England)|October 15, 2016
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationaleSteven J Isakoff, Shannon Puhalla, Susan M Domchek, et al.Gynecologic Oncology|January 3, 2016
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapySusan M Domchek, Carol Aghajanian, Ronnie Shapira-Frommer, et al.The Lancet. Oncology|June 3, 2014
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trialJonathan Ledermann, Philipp Harter, Charlie Gourley, et al.The Lancet. Oncology|September 13, 2016
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trialJonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2011
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancerStan B Kaye, Jan Lubinski, Ursula Matulonis, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2022
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 StudyBenoit You, Vasudha Sehgal, Balakrishna Hosmane, et al.European Journal of Cancer (Oxford, England : 1990)|June 25, 2025
Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms resultsRobert L Coleman, Gini F Fleming, Mark F Brady, et al.Gynecologic Oncology|June 23, 2019
PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumorsMonica Tang, Rachel L O'Connell, Frederic Amant, et al.Pageof 25